



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

TY-51469

Cat. No.:	HY-12370
CAS No.:	603987-59-3
Molecular Formula:	C ₂₀ H ₁₅ FN ₂ O ₆ S ₄
Molecular Weight:	526.6
Target:	Proteasome
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (63.29 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.8990 mL	9.4949 mL	18.9897 mL
	5 mM		0.3798 mL	1.8990 mL	3.7979 mL
	10 mM		0.1899 mL	0.9495 mL	1.8990 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	TY-51469 is a chymase inhibitor with IC ₅₀ s for simian and human chymases of 0.4 and 7.0 nM, respectively.
IC ₅₀ & Target	IC ₅₀ : 0.4 nM (Simian chymase), 0.7 nM (Human chymase) ^[1]
In Vivo	TY-51469 shows 100% stability in rat plasma at 40°C for as long as 1 hour^[1]. TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[1]	Rats^[1] The 2-week intravenous repeated-dose toxicity study of TY-51469 was conducted in male Sprague-Dawley rats at daily doses of 0 (control), 20, and 60 mg/kg^[1].
--------------------------------------	---

Mice^[1]

the chymase inhibitor TY-51469 was administered daily at a dose of 0.1 or 1.0 mg/kg/day for 21 days using an osmotic pump to male 8-week-old ICR mice. The osmotic pump released the drug solution continuously at a rate of 0.3 μ L/h for 21 days^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Takato H, et al. The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice. Expert Opinion on Therapeutic Targets Volume 15, 2011 - Issue 4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA